Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Real-time Estimate Cboe BZX  -  03:27 2022-12-09 pm EST
248.74 USD   +0.31%
10:13aBD Releases 2022 Global Inclusion Diversity and Equity Annual Report
AQ
12/08BD Releases 2022 Global Inclusion, Diversity and Equity Annual Report
PR
12/08BECTON, DICKINSON AND COMPANY : Ex-dividend day for
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Becton Dickinson and : BD Expands Voluntary Recall of ChloraPrep™ 3 mL Applicator Nationwide to Include All U.S. States

03/24/2021 | 01:55pm EST

FRANKLIN LAKES, N.J. (March 24, 2021)- BD (Becton, Dickinson and Company), a leading global medical technology company, has revised its press release dated March 19, 2021 relating to an expanded voluntary recall that was initiated on June 23, 2020 for specified catalog numbers of the ChloraPrep 3 mL applicator due to possible fungal contamination under certain environmental conditions.

BD has determined that storage of the ChloraPrep 3 mL Applicator in regions of the world with high heat and humidity, where product may be exposed to temperatures of 30 degrees Celsius (86 degrees Fahrenheit) and 75% relative humidity, allows the growth of Aspergillus penicillioides.

The Aspergillus penicillioides within the packaging can contaminate the surface of the applicator and/or gloved hands of the health care professional and then consequently the sterile field. Since the applicator is used for site preparation prior to an invasive procedure, a contaminated applicator can result in direct inoculation of the fungus into tissues. To date, no complaints, adverse events, injuries, or deaths have been reported related to this voluntary recall.

Contamination of skin preparation products with Aspergillus penicillioides may lead to serious systemic infection, sepsis, illness, and death. If the fungus is introduced in the patient's bloodstream during placement of an intravascular catheter, the catheter would most likely have to be removed, necessitating another procedure. Aspergillus penicillioides infection of a surgical site may result in the need for medical and surgical interventions and long-term treatment with antifungal drugs.

This recall does not include 3 mL applicators found in kits. It also does not include any other ChloraPrep™ product presentations. All other ChloraPrep™ products are manufactured with different packaging materials that are not affected by this issue. BD is implementing a global packaging change for the 3 mL product to correct this issue, which is expected to be available by the end of April in the United States. The implementation time for other countries will vary based on registration requirements.

As part of the voluntary recall to the user level, the company will notify customers and distributors affected by the recall. BD is instructing customers and distributors to discard all remaining inventory of the impacted ChloraPrep™ 3 mL applicators (see list of impacted catalog numbers below) and committed to replacing product affected by the recall.

Affected Catalog Numbers in the United States

260400

ChloraPrep® One-Step 3 mL Applicator - Clear

260415

ChloraPrep® One-Step 3 mL Applicator - Hi-Lite Orange

930400

BD ChloraPrep™ Clear 3 mL Applicator

930415

BD ChloraPrep™ Hi-Lite Orange™ 3 mL Applicator

Customer inquiries related to this recall, as well as adverse reaction/events experienced with the product should be addressed to BD Customer Support: 1-800-526-4455 (Toll Free) between the hours of 8:30 a.m. and 6 p.m. ET.

FDA MedWatch Reporting

Adverse reactions/events experienced with the use of any of these products should also be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

# # #

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Troy Kirkpatrick Kristen M. Stewart, CFA
BD Public Relations BD Investor Relations
858.617.2361 201.847.5378
troy.kirkpatrick@bd.comkristen.stewart@bd.com

Disclaimer

BD - Becton, Dickinson and Company published this content on 24 March 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 March 2021 18:54:03 UTC.


ę Publicnow 2021
All news about BECTON, DICKINSON AND COMPANY
10:13aBD Releases 2022 Global Inclusion Diversity and Equity Annual Report
AQ
12/08BD Releases 2022 Global Inclusion, Diversity and Equity Annual Report
PR
12/08BECTON, DICKINSON AND COMPANY : Ex-dividend day for
FA
12/07BD Named in top 25% of Newsweek's 2023 List of America's Most Responsible Companies
PR
11/29Transcript : Becton, Dickinson and Company Presents at 5th Annual Evercore IS..
CI
11/29Distinct Elements Or Parts Of A Whole? Obviousness Challenge Denied In SolarEdge Techs...
AQ
11/23AngioDynamics Disagrees With Jury Decision on Patent-Infringement Verdict, Plans to App..
MT
11/23Goldman Sachs Adjusts Becton, Dickinson and Co.'s Price Target to $272 From $319, Keeps..
MT
11/23Jury Hits AngioDynamics With Patent-Infringement Verdict
DJ
11/22BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2023 18 776 M - -
Net income 2023 1 870 M - -
Net Debt 2023 11 802 M - -
P/E ratio 2023 36,0x
Yield 2023 1,50%
Capitalization 70 269 M 70 269 M -
EV / Sales 2023 4,37x
EV / Sales 2024 4,05x
Nbr of Employees 77 000
Free-Float 77,4%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 247,97 $
Average target price 265,69 $
Spread / Average Target 7,15%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Christopher J. DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Elizabeth McCombs Senior Vice President-Research & Development
Joseph M. Smith Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY0.29%70 269
ABBOTT LABORATORIES-25.53%186 423
MEDTRONIC PLC-25.65%103 475
DEXCOM, INC.-12.16%47 382
AMERISOURCEBERGEN CORPORATION28.14%35 059
HOYA CORPORATION-21.68%34 966